Neurostimulation for Parkinson's disease with early motor complications

New England Journal of Medicine

Volumn 368, Issue 7, 2013, Pages 610-622

  Schuepbach, W M M ^a   Rau, J ^l   Knudsen, K ^m   Volkmann, J ^m   Krack, P ^c   Timmermann, L ^o   Halbig T D ^a   Hesekamp, H ^a   Navarro, S M ^b   Meier, N ^a   Falk, D ⁿ   Mehdorn, M ⁿ   Paschen, S ^m   Maarouf, M ^o   Barbe, M T ^o   Fink, G R ^o   Kupsch, A ^p   Gruber, D ^p   Schneider, G H ^p   Seigneuret, E ^c   Kistner, A ^c   Chaynes, P ^d   Ory Magne, F ^d   Brefel Courbon, C ^d   Vesper, J ^q   Schnitzler, A ^q   Wojtecki, L ^q   Houeto, J L ^e   Bataille, B ^e   Maltete D ^f   Damier, P ^g   Raoul, S ^g   Sixel Doering, F ^r   Hellwig, D ^l   Gharabaghi, A ^s   Kruger R ^t   Pinsker, M O ^u   Amtage, F ^u   Regis J M ^h   Witjas, T ⁱ   Thobois, S ^j   Mertens, P ^k   Kloss, M ^v   Hartmann, A ^a   Oertel, W H ^l   Post, B ^w   Speelman, H ^x   Agid, Y ^a   Schade Brittinger, C ^l   Deuschl, G ^m   more..

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE POITIERS   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ TIMONE HOSPITAL   (France)

^j UNIVERSITÉ LYON 1   (France)

^k University Hospital   (France)

^l PHILIPPS UNIVERSITY MARBURG   (Germany)

^m UNIVERSITY OF KIEL   (Germany)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o UNIVERSITY OF COLOGNE   (Germany)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q HEINRICH HEINE UNIVERSITY   (Germany)

^r Paracelsus Elena Klinik   (Germany)

^s UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^t UNIVERSITY OF TÜBINGEN   (Germany)

^u UNIVERSITY OF FREIBURG   (Germany)

^v UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^w RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^x UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE DURATION; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR DYSFUNCTION; NERVE STIMULATION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RATING SCALE; SUBTHALAMUS; SUICIDAL IDEATION; SUICIDE ATTEMPT;

EID: 84873675072     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1205158     Document Type: Article

References (37)

1. Vidailhet M. Movement disorders in 2010: Parkinson disease - symptoms and treatments. Nat Rev Neurol 2011;7:70-2.
2. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-8.
3. Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord 2009;24:813-8.
4. Post B, Muslimovic D, van Geloven N, Speelman JD, Schmand B, de Haan RJ. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Mov Disord 2011;26:449-56.
5. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-11.
6. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21:Suppl 14:S290-S304.
7. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908. [Erratum, N Engl J Med 2006;355:1289.]
8. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-91.
9. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-91.
10. Okun MS, Gallo BV, Mandybur G, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol 2012;11:140-9. [Erratum, Lancet Neurol 2012;11:208.]
11. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-34.
12. Fasano A, Romito LM, Daniele A, et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010;133:2664-76.
13. Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010;25:578-86.
14. Marinus J, Visser M, Martínez-Martín P, van Hilten JJ, Stiggelbout AM. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 2003;56:61-7.
15. Schüpbach WM, Maltête D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007;68:267-71.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
17. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Health Care Information, 1987:153-63.
18. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148-56.
19. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu T, eds. Geriatric psychiatry. New York: Grune and Stratton, 1976:77-121.
20. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
21. Deuschl G, Schüpbach WMM, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013;19:56-61.
22. Post B, Merkus MP, de Bie RM, de Haan RJ, Speelman JD. Unified Parkinson's Disease Rating Scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? Mov Disord 2005;20:1577-84.
23. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease - report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13:1186-202.
24. Fitzpatrick R, Peto V, Jenkinson C, Greenhall R, Hyman N. Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders. Mov Disord 1997;12:916-22.
25. Martinez-Martin P, Jeukens-Visser M, Lyons KE, et al. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord 2011;26:2371-80.
26. Flemenbaum A, Zimmermann RL. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep 1973;32:783-92.
27. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
28. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:134-9.
29. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-53.
30. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21.
31. Beunckens C, Molenberghs G, Kenward M. Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials. Clin Trials 2005;2:379-86.
32. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
33. Smeding HM, Speelman JD, Huizenga HM, Schuurman PR, Schmand B. Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82:754-60.
34. Daniels C, Krack P, Volkmann J, et al. Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson's disease predictable? Mov Disord 2011;26:2516-21.
35. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 2001;30:299-302.
36. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008;131:2720-8.
37. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26:Suppl 3:S2-S41.